Ondine Biomedical Inc.

www.ondinebio.com

Logo

Address:

888 – 1100 Melville Street

Vancouver BC

V6E 4A6

Canada

Phone: 604-669-0555

Fax: 604-669-0533

Member Sector: Biopharmaceuticals

Ondine Biomedical Inc. is developing non-antibiotic therapies for the treatment of a wide variety of complex bacterial, fungal and viral infections. The Company is focused on developing and commercializing innovative products using its patented light-activated platform technology, Photodynamic disinfection (PDD). PDD eradicates pathogens by using a non-thermal light source with a specific wave length and a photosensitizing solution that selectively stains the targeted pathogens. The PDD treatment does not harm human tissue and provides an immediate broad-spectrum antimicrobial efficacy without the development of bacterial resistance to the therapy. Ondine’s first product, Periowave, was introduced into the dental market in 2006 for the treatment of periodontal disease. Ondine’s second product,MRSAid (Steriwave), is for decolonization of pathogens from the nares of pre-operative hospital patients.MRSAid (Steriwave) was introduced in later part of 2012 at the conclusion of its successful deployment in a quality improvement project conducted at Vancouver General Hospital. Ondine continues to develop a number of other applications of PDD, including Exelumea, which eradicates bacterial biofilms on the inner surface of endotracheal tubes thereby reducing the risk to patients on long-term intubation of contracting ventilator-associated pneumonia. Ondine is headquartered in Vancouver, British Columbia, Canada, and has a research and development laboratory in Bothell, Washington, USA.   03.16.2016 – CANADIAN PHOTODISINFECTION TECHNOLOGY HEADS TO CHINA